| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Nikhil Lalwani
Also a director
President and Chief Executive Officer
|
48 | Not stated | $10,278,620 | |
|
Stephen P. Carey
Senior Vice President, Finance and Chief Financial Officer
|
55 |
Since 2020
6 years
|
$3,251,862 | |
|
Krista Davis
Senior Vice President and Chief Human Resources Officer
|
53 |
Since 2022
4 years
|
Not reported | |
|
Meredith W. Cook
SR. VP, GENERAL COUNSEL & SEC.
Title from the Form 4 dated Nov 13, 2026
|
52 | Not stated | $2,318,421 | |
|
Muthusamy Shanmugam
Head of Research & Development and Chief Operating Officer of New Jersey Operations
|
58 | Not stated | Not reported | |
|
Chad Gassert
Senior Vice President, Corporate Development & Strategy
|
50 |
Since 2021
5 years
|
Not reported | |
|
Ori Gutwerg
Senior Vice President, Generics
|
52 |
Since 2021
5 years
|
$2,309,559 | |
|
Christopher K. Mutz
Senior Vice President, Head of Rare Disease
|
55 |
Since 2021
5 years
|
$3,396,694 | |
|
Thomas Rowland
Senior Vice President, Head of Established Brands
|
60 |
Since 2021
5 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 9, 2026 · updated by the 8-K of Aug 24, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Thomas J. Haughey
Board chair
|
62 |
2018
8 years
|
Independent |
Audit and Finance
|
None stated | $343,089 | |
|
Nikhil Lalwani
CEO
|
48 |
2020
6 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Matthew J. Leonard
|
60 |
2023
3 years
|
Independent |
Audit and Finance
|
None stated | $327,573 | |
|
Antonio R. Pera
|
68 |
2020
6 years
|
Independent |
Compensation · Chair
|
None stated | $327,573 | |
|
Renee P. Tannenbaum
|
74 |
2022
4 years
|
Independent |
Compensation
Nominating and Corporate Governance · Chair
|
Cardiff Oncology, Inc. | $332,573 | |
|
Jeanne A. Thoma
|
66 |
2020
6 years
|
Independent |
Audit and Finance · Chair
Compensation
|
Nanoform Finland Oyj | $331,330 | |
|
Henry Gosebruch
Joined Aug 19, 2026
|
- | - | - | - | - | - | |
|
Patrick D. Walsh
Leaving at the meeting
|
Not stated | Not stated | Independent | None stated | None stated | $345,800 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 9, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...